Bain Capital Life Sciences Investors, LLC - Q4 2020 holdings

$1.59 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 26 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 57.1% .

 Value Shares↓ Weighting
DRNA SellDICERNA PHARMACEUTICALS INC$67,858,000
-7.6%
3,080,237
-24.5%
4.26%
-37.7%
KYMR SellKYMERA THERAPEUTICS INC.$29,735,000
+26.1%
479,605
-34.3%
1.87%
-15.0%
MRNS SellMARINUS PHARMACEUTICALS INC$17,459,000
-5.1%
1,431,058
-0.0%
1.10%
-36.1%
PANAU ExitPANACEA ACQUISITION CORPunit 99/99/9999$0-500,000
-100.0%
-0.47%
SAGE ExitSAGE THERAPEUTICS, INC.$0-499,100
-100.0%
-2.84%
DVAX ExitDYNAVAX TECHNOLOGIES CORP.$0-10,895,773
-100.0%
-4.39%
REPL ExitREPLIMUNE GROUP INC$0-2,122,415
-100.0%
-4.55%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Bain Capital Life Sciences Partners, LP #1
  • Bain Capital Life Sciences Fund, L.P. #2
  • BC SW, LP #3
  • Bain Capital Life Sciences Investors II, LLC #4
  • Bain Capital Life Sciences Fund II, L.P. #5
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
APTINYX INC20Q1 202316.9%
SOLID BIOSCIENCES INC19Q3 202222.2%
SPRINGWORKS THERAPEUTICS INC17Q3 202341.8%
DICERNA PHARMACEUTICALS INC16Q3 202158.6%
DYNAVAX TECHNOLOGIES CORP.16Q3 202312.4%
SAVARA INC16Q3 20236.0%
X4 PHARMACEUTICALS INC16Q3 20233.2%
ARCUTIS BIOTHERAPEUTICS, INC.15Q3 202320.1%
MERSANA THERAPEUTICS, INC.14Q3 20238.4%
CRINETICS PHARMACEUTICALS, INC.14Q3 20235.4%

View Bain Capital Life Sciences Investors, LLC's complete holdings history.

Latest filings
TypeFiled
42024-02-14
13F-HR2024-02-13
32024-02-07
42024-01-12
32023-12-29
13F-HR2023-11-14
13F-HR2023-08-14
32023-05-30
42023-05-30
13F-HR2023-05-15

View Bain Capital Life Sciences Investors, LLC's complete filings history.

Compare quarters

Export Bain Capital Life Sciences Investors, LLC's holdings